IP Library Granted Patent US 6,900,175
Granted Patent B2
US 6,900,175 · App. 10/714,261 · Granted May 31, 2005

Methods of administering dalbavancin for treatment of bacterial infections

Assignee: Vicuron Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,900,175
App. No.
10/714,261
Granted
May 31, 2005
Kind
B2
Abstract

The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.

Claims (26)

1. A method for treating a bacterial infection in a human in need thereof, the method comprising:

administering initial and subsequent therapeutically effective doses of dalbavancin in a pharmaceutically acceptable carrier to the patient,

wherein each dose is separated by five to ten days and wherein the amount of the initial dose is about 500 mg to about 5000 mg, and wherein the amount of the initial dose is at least about two times the amount of dalbavancin contained in the subsequent dose.

2. The method of claim 1 , the method comprising administering a single subsequent dose.

3. The method of claim 2 , wherein the subsequent dose is administered about one week after the initial dose without any intervening dose of dalbavancin.

4. The method of claim 1 , the method comprising administering multiple subsequent doses.

5. The method of claim 4 , wherein said subsequent doses are administered at about one week intervals without any intervening doses of dalbavancin.

6. The method of claim 1 , wherein the bacterial infection is a skin and soft tissue infection.

7. The method of claim 1 , wherein the amount of the initial dose is about 1500 mg.

8. The method of claim 1 , wherein the amount of the initial dose is about 1000 mg.

9. The method of claim 1 , wherein the amount of the initial dose is about 800 mg.

10. The method of claim 1 , wherein the amount of the initial dose is about 500 mg.

11. The method of claim 1 , wherein the amount of each subsequent dose is about 400 mg to about 1000 mg.

12. The method of claim 1 , wherein the amount of each subsequent dose is about 500 mg.

13. The method of claim 1 , wherein the amount of each subsequent dose is about 400 mg.

14. The method of claim 1 , wherein the amount of each subsequent dose is about 250 mg.

15. The method of claim 1 , wherein the amount of each subsequent dose is about 200 mg.

16. The method of claim 1 , wherein the amount of the initial dose is about 1000 mg and the amount of each subsequent dose is about 250 mg.

17. A method for treating a bacterial infection in a human in need thereof, the method comprising:

administering initial and subsequent therapeutically effective doses of dalbavancin in a pharmaceutically acceptable carrier to the patient,

wherein each dose is separated by about one week and wherein the amount of the initial dose is about 1000 mg and the amount of each subsequent dose is about 500 mg.

18. The method of claim 17 , the method comprising administering a single subsequent dose.

19. The method of claim 17 , wherein the subsequent dose is administered about one week after the initial dose without any intervening dose of dalbavancin.

20. The method of claim 17 , the method comprising administering multiple subsequent doses.

21. The method of claim 20 , wherein said subsequent doses are administered at about one week intervals without any intervening doses of dalbavancin.

22. The method of claim 17 , wherein the bacterial infection is a skin and soft tissue infection.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2023
From: VICURON PHARMACEUTICALS LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 064471/0932 →
CHANGE OF NAME Recorded Aug 28, 2020
From: VICURON PHARMACEUTICALS INC.
To: VICURON PHARMACEUTICALS LLC
Reel/Frame 053634/0231 →
RELEASE OF SECURITY INTEREST Recorded Dec 17, 2014
From: PDL BIOPHARMA, INC.
To: VICURON PHARMACEUTICALS INC.
Reel/Frame 034527/0843 →
SECURITY AGREEMENT Recorded Oct 31, 2013
From: VICURON PHARMACEUTICALS INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 031529/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2004
From: CAVALERI, MARCO; JABES, DANIELA; HENKEL, TIMOTHY; MALABARBA, ADRIANO; MOSCONI, GIORGIO; STOGNIEW, MARTIN; WHITE, RICHARD J.
To: VICURON PHARMACEUTICALS INC.
Reel/Frame 015174/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2004
From: CAVALERI, MARCO; JABES, DANIELA; HENKEL, TIMOTHY; MALABARBA, ADRIANO; MOSCONI, GIORGLO; STOGNIEW, MARTIN; WHITE, RICHARD J.
To: VICURON PHARMACEUTICALS INC.
Reel/Frame 014478/0965 →
Continuity (5)
Provisional Application 6042765400 · Nov 18, 2002
Provisional Application 6048569400 · Jul 8, 2003
Provisional Application 6049504800 · Aug 13, 2003
Provisional Application 6049648300 · Aug 19, 2003
Related Publication 20040142883A1 · Jul 22, 2004